Medical devices maker AngioDynamics Q1 net sales beats estimates, raises annual rev guidance

AngioDynamics

02/10/2025 11:16

Overview

AngioDynamics fiscal Q1 net sales rise 12.2%, beating analyst expectations

Adjusted EPS and adj net income beat estimates, per LSEG data

Co raises FY 2026 guidance for net sales, adjusted EBITDA

Outlook

AngioDynamics raises FY 2026 net sales guidance to $308-$313 mln

Company increases FY 2026 Med Tech net sales growth forecast to 14%-16%

AngioDynamics expects FY 2026 adjusted EBITDA of $6-$10 mln

Company maintains expectation of positive cash flow for FY 2026

Result Drivers

MED TECH GROWTH - Med Tech segment reported a 26.1% increase in net sales, driven by strong performance across Auryon, Mechanical Thrombectomy, and NanoKnife platforms

THROMBUS MANAGEMENT - Mechanical Thrombectomy business, including AngioVac and AlphaVac, saw a 41.2% sales increase

GROSS MARGIN IMPROVEMENT - Gross margin rose by 90 basis points year-over-year, attributed to higher Med Tech revenue and operational efficiencies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$75.7 mln
$72.70 mln (4 Analysts)
Q1 Adjusted EPS
Beat
-$0.1
-$0.12 (4 Analysts)
Q1 Adjusted Net Income
Beat
-$4.20 mln
-$4.73 mln (4 Analysts)
Q1 Net Income
-$10.90 mln
Q1 Adjusted EBITDA
Beat
$2.20 mln
-$1.05 mln (2 Analysts)
Q1 Gross Margin
55.3%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for AngioDynamics Inc is $16.50, about 32.9% above its October 1 closing price of $11.07

Press Release: ID:nBw5xpX8ga

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)